Immunogenicity of one and two doses of Gardasil®9 in Tanzanian girls in the DoRIS Trial

Tanzanian girls received one to three doses of Gardasil®9 in the DoRIS randomised trial. Blood samples from one and two-dose Gardasil®9 recipients were collected at months (M)0, M7, M12, M24, and M36 for testing via an HPV Multiplex immunoassay. All participants were HPV 16, HPV 31, and HPV 58 seropositive at M36. For the one-dose group, 96.8-98.2% of girls were seropositive for HPV 11, HPV 18, and HPV 33 and 73.0-87.7% seropositive for HPV 6, HPV 45 and HPV 52. For the two-dose group, all participants were HPV 6, HPV 11, HPV 18, and HPV 33 seropositive, while 98.6% seropositive for HPV 45 and HPV 52. Geometric mean concentrations (GMCs) were higher in the two-dose group compared to the one-dose group but all GMCs in the one-dose group had plateaued by M24 and remained stable to M36. HPV vaccine immune responses in this study will continue through nine years post-vaccination. ClinicalTrials.gov ID: NCT02834637; Registration Date: 2016-06-29; https://www.clinicaltrials.gov/study/NCT02834637 .

Authors

Institutions

Publication Details

Journal
npj Vaccines
Published
2025-12-19
DOI
https://doi.org/10.1038/s41541-025-01344-1
Primary Topic
Immunotherapy and Immune Responses
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Immunogenicity of one and two doses of Gardasil®9 in Tanzanian girls in the DoRIS Trial

Hilary Whitworth, Saidi Kapiga, Troy J. Kemp, Jackton Indangasi et al.
npj Vaccines
Immunotherapy and Immune Responses
article

Immunogenicity of one and two doses of Gardasil®9 in Tanzanian girls in the DoRIS Trial

Hilary Whitworth, Saidi Kapiga, Troy J. Kemp, Jackton Indangasi, Lígia A. Pinto, John Changalucha, Ramadhan Hashim, Charles Lacey, Richard Hayes, David Mwanzalima, Deborah Watson-Jones, Kathy Baisley
article en

Abstract

Tanzanian girls received one to three doses of Gardasil®9 in the DoRIS randomised trial. Blood samples from one and two-dose Gardasil®9 recipients were collected at months (M)0, M7, M12, M24, and M36 for testing via an HPV Multiplex immunoassay. All participants were HPV 16, HPV 31, and HPV 58 seropositive at M36. For the one-dose group, 96.8-98.2% of girls were seropositive for HPV 11, HPV 18, and HPV 33 and 73.0-87.7% seropositive for HPV 6, HPV 45 and HPV 52. For the two-dose group, all participants were HPV 6, HPV 11, HPV 18, and HPV 33 seropositive, while 98.6% seropositive for HPV 45 and HPV 52. Geometric mean concentrations (GMCs) were higher in the two-dose group compared to the one-dose group but all GMCs in the one-dose group had plateaued by M24 and remained stable to M36. HPV vaccine immune responses in this study will continue through nine years post-vaccination. ClinicalTrials.gov ID: NCT02834637; Registration Date: 2016-06-29; https://www.clinicaltrials.gov/study/NCT02834637 .

npj VaccinesVol. 11(1)
Leidos (United States) (US), London School of Hygiene & Tropical Medicine (GB), Frederick National Laboratory for Cancer Research (US), Mwanza Intervention Trials Unit (TZ), Leidos Biomedical Research Inc. (United States), University of York (GB)
U.S. Department of Health and Human Services, Bill and Melinda Gates Foundation, Wellcome Trust, Frederick National Laboratory for Cancer Research, Department of Health and Social Care, Foreign, Commonwealth and Development Office, National Institutes of Health, Medical Research Council, National Cancer Institute
Openalex Percentile: Top 53%
Immunotherapy and Immune Responses
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.